Barbara Harlin Bispham Sells 620 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock

Crescent Biopharma, Inc. (NASDAQ:CBIO) insider Barbara Bispham sold 620 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $17.90, for a total value of $11,098.00. Following the completion of the transaction, the insider directly owned 18,710 shares of the company’s stock, valued at $334,909. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Barbara Harlin Bispham also recently made the following trade(s):

• On Monday, June 22nd, Barbara Bispham sold 1,218 shares of Crescent Biopharma stock. The stock was sold at an average price of $17.99, for a total value of $21,911.82.

Crescent Biopharma Price Performance

Crescent Biopharma stock traded up $0.12 during trading hours on Friday, hitting $16.89. The stock had a trading volume of 3,123,507 shares, compared to its average volume of 294,314. The stock has a market capitalization of $627.36 million, a price-to-earnings ratio of -2.51 and a beta of 1.24. Crescent Biopharma, Inc. has a 1-year low of $8.72 and a 1-year high of $27.41. The stock’s fifty day moving average is $17.12 and its two-hundred day moving average is $17.43.

Crescent Biopharma (NASDAQ:CBIO) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.74). As a group, sell-side analysts anticipate that Crescent Biopharma, Inc. will post -2.91 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BVF Inc. IL boosted its stake in shares of Crescent Biopharma by 98.1% during the 4th quarter. BVF Inc. IL now owns 2,748,763 shares of the biopharmaceutical company’s stock worth $32,600,000 after purchasing an additional 1,360,900 shares during the last quarter. Fcpm Iii Services B.V. acquired a new position in shares of Crescent Biopharma in the fourth quarter valued at approximately $19,899,000. Opaleye Management Inc. raised its position in shares of Crescent Biopharma by 0.5% in the second quarter. Opaleye Management Inc. now owns 1,319,351 shares of the biopharmaceutical company’s stock valued at $23,748,000 after buying an additional 6,736 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Crescent Biopharma during the second quarter valued at approximately $22,892,000. Finally, NEXTBio Capital Management LP purchased a new position in shares of Crescent Biopharma during the fourth quarter valued at approximately $4,422,000. 75.19% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Crescent Biopharma in a report on Friday, August 7th. Wedbush reissued an “outperform” rating and set a $27.00 price objective on shares of Crescent Biopharma in a research note on Monday. HC Wainwright restated a “neutral” rating on shares of Crescent Biopharma in a research report on Thursday, July 16th. Finally, TD Cowen raised Crescent Biopharma to a “strong-buy” rating in a research note on Monday, August 24th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Crescent Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $29.60.

Crescent Biopharma News Summary

Here are the key news stories impacting Crescent Biopharma this week:

• Neutral Sentiment: CEO Joshua Brumm, COO Jonathan McNeill, CFO Richard Scalzo, and other insiders collectively sold 16,726 shares worth approximately $285,501 between September 16 and September 18. The sales reduced individual holdings by roughly 0.5% to 3.2%, but insiders continued to retain meaningful positions. SEC insider transaction filing
• Neutral Sentiment: All reported transactions were executed under pre-arranged Rule 10b5-1 trading plans and were described as sales to cover tax-withholding obligations tied to vested equity awards. That reduces the likelihood that the transactions represent a change in management’s outlook, although the aggregate selling may still weigh modestly on sentiment. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by senior executives—including the CEO and COO—could be viewed as a near-term supply or sentiment overhang. However, the relatively small percentage reductions and tax-related rationale make this a limited negative signal rather than a clear indication of weakening business prospects. SEC insider transaction filing

About Crescent Biopharma

Crescent Biopharma, Inc (NASDAQ: CBIO) is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company’s activities center on research, preclinical development and clinical evaluation of investigational drug candidates.

Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources.

The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships.